Drug Trial Radar · NCT04906083
Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
Last checked: Nov 20, 2026Latest source record: Jun 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Feb 1, 2021
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Anhui Provincial Hospital; The First Affiliated Hospital of Nanchang University; Taihe Hospital, Hubei University of Medicine; The First Hospital of Jilin University
- First posted
- May 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
End stage liver disease is prone to thrombocytopenia. This study is a multi-center, randomized, prospective, randomized controlled Phase IV Clinical trial to discuss the Efficacy and Safety of Avatrombopag in Patients with End-stage Liver Disease and Thrombocytopenia.
Conditions
- Liver Failure
- Thrombocytopenia
- Decompensated Cirrhosis
Interventions
AvatrombopagDrug
Avatrombopag: PLT:30\~50×10\^9/L patients, 40 mg/d; PLT:\<30×10\^9/L patients, 60 mg/d.
Standard medical treatmentDrug
Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Platelet count response timeTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of infectious disease, Tongji Hospital
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.